An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Catalent Appoints Sridhar Krishnan to Lead New Global Operational Excellence Strategy, “The Catalent Way”
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
management
Rhea-AI Summary
Catalent, Inc. (NYSE: CTLT) has appointed Sridhar Krishnan as Vice President of The Catalent Way, a newly created role focused on operational excellence through Lean principles. Krishnan will lead the company’s transformation strategy to promote sustainable execution and growth, while also being part of the Executive Leadership Team under Alessandro Maselli, President & CEO. He brings over 20 years of operational leadership experience, including previous roles at Catalent and Jubilant Pharma. His expertise will aid in implementing continuous improvement processes across Catalent's 50 global facilities.
Positive
Appointment of Sridhar Krishnan expected to enhance operational excellence through Lean principles.
Leadership change may provide fresh perspectives to drive sustainable growth.
Krishnan's extensive experience in operational leadership could strengthen company performance.
Negative
None.
SOMERSET, N.J.--(BUSINESS WIRE)--
Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced the appointment of Sridhar Krishnan, to the newly created position of Vice President, The Catalent Way, where he will lead the company’s operational excellence strategy and spearhead a transformation based on Lean principles, designed to drive sustainable execution excellence, enabling growth. He will also serve on the Executive Leadership Team, reporting directly to Catalent’s President & Chief Executive Officer, Alessandro Maselli.
Sridhar Krishnan, who joins Catalent as Vice President, "The Catalent Way", which is a company-wide transformation based on Lean principles and designed to drive sustainable execution excellence. (Photo: Business Wire)
The Catalent Way is a company-wide system of continuous improvement with clear standards to enable more predictable and efficient processes. Mr. Krishnan will work alongside senior executives across the company’s business segments, and more than 50 global facilities, to implement this strategy.
Mr. Krishnan returns to Catalent having spent the previous four years in a number of roles within the pharmaceutical industry, most recently as SVP, Head of Operations, for Jubilant Pharma. He has over 20 years of operational leadership experience within the CDMO space, including as Vice President of Global Operations, and subsequently as Vice President, Global Procurement & Business Analytics at Catalent. He holds a bachelor’s degree in mechanical engineering and is a Six Sigma Master Black Belt.
Commenting on the appointment, Alessandro Maselli said, “Sridhar brings considerable operational leadership and Lean expertise, as well as a proven track record driving enterprise-wide business transformations and operational performance. We welcome him back to Catalent, in a role where he will provide the key strategic focus necessary to not only establish new standards of excellence at Catalent, but within the pharmaceutical industry.”
Notes for Editors
About Catalent, Inc.
Catalent, Inc. (NYSE: CTLT), an S&P 500® company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world.
With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually.
Catalent’s expert workforce of approximately 18,000 includes more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information www.catalent.com.
More products. Better treatments. Reliably supplied.™
Forward Looking Statements
This release contains both historical and forward-looking statements. All statements other than statements of historical fact, are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of statements that include phrases such as “believe,” “expect,” “anticipate,” “intend,” “estimate,” “plan,” “project,” “predict,” “hope,” “foresee,” “likely,” “may,” “could,” “target,” “will,” “would,” or other words or phrases with similar meanings. Similarly, statements that describe Catalent’s objectives, plans, or goals are, or may be, forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Catalent’s expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited to, the following: the current or future effects of the COVID-19 pandemic or any global health developments on Catalent's or its customers' or suppliers' businesses; participation in a highly competitive market and increased competition that may adversely affect Catalent’s business; demand for its offerings, which depends in part on its customers’ research and development and the clinical and market success of their products; product and other liability risks that could adversely affect Catalent’s results of operations, financial condition, liquidity and cash flows; failure to comply with existing and future regulatory requirements; failure to provide quality offerings to customers could have an adverse effect on Catalent’s business and subject it to regulatory actions and costly litigation; problems providing the highly exacting and complex services or support required; global economic, political and regulatory risks to Catalent’s operations, including risks from rising inflation, disruptions to global supply chains, or from the Ukrainian-Russian war; inability to enhance existing or introduce new technology or service offerings in a timely manner; inadequate patents, copyrights, trademarks and other forms of intellectual property protections; fluctuations in the costs, availability, and suitability of the components of the products Catalent manufactures, including active pharmaceutical ingredients, excipients, purchased components and raw materials; changes in market access or healthcare reimbursement in the United States or internationally; fluctuations in the exchange rate of the U.S. dollar against other currencies; adverse tax legislative or regulatory initiatives or challenges or adjustments to Catalent’s tax positions; loss of key personnel; risks generally associated with information systems; inability to complete any future acquisition or other transaction that may complement or expand its business or divest of non-strategic businesses or assets and difficulties in successfully integrating acquired businesses and realizing anticipated benefits of such acquisitions; risks associated with timely and successfully completing, and correctly anticipating the future demand predicted for, capital expansion projects at existing facilities; offerings and customers’ products that may infringe on the intellectual property rights of third parties; environmental, health, and safety laws and regulations, which could increase costs and restrict operations; labor and employment laws and regulations or labor difficulties, which could increase costs or result in operational disruptions; additional cash contributions required to fund Catalent’s existing pension plans; substantial leverage that may limit its ability to raise additional capital to fund operations and react to changes in the economy or in the industry; and exposure to interest-rate risk to the extent of its variable-rate debt preventing it from meeting its obligations under its indebtedness. For a more detailed discussion of these and other factors, see the information under the caption “Risk Factors” in Catalent’s Annual Report on Form 10-K for the fiscal year ended June 30, 2022, filed August 29, 2022. All forward-looking statements speak only as of the date of this release or as of the date they are made, and Catalent does not undertake to update any forward-looking statement as a result of new information or future events or developments except to the extent required by law.
Sridhar Krishnan is the newly appointed Vice President of The Catalent Way, responsible for leading the operational excellence strategy.
What is 'The Catalent Way'?
'The Catalent Way' is a company-wide transformation initiative based on Lean principles aimed at driving sustainable execution excellence.
What experience does Sridhar Krishnan bring to Catalent?
Krishnan has over 20 years of operational leadership experience in the pharmaceutical industry, including significant roles at Catalent and Jubilant Pharma.
How may Sridhar Krishnan's appointment impact Catalent's future?
His leadership is expected to implement continuous improvement strategies that could enhance operational efficiency and support growth.
When was the appointment of Sridhar Krishnan announced?
The appointment was announced in a press release dated March 6, 2023.
